Lupin receives tentative US FDA Approval for Ziprasidone

BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, 21st May 2007: Lupin Ltd., announced today that it has received tentative approval from the US FDA for it's Abbreviated New Drug Application (ANDA) for Ziprasidone Capsules 20mg, 40mg and 60mg. Ziprasidone, an antipsychotic drug, is indicated for the treatment of schizophrenia and bipolar disorder. Given that the company filed the ANDA on the earliest possible NCE date, this ensures that there will be limited competition when the product goes generic.

Lupin's Ziprasidone Capsules are the AB-rated generic equivalent of Pfizer's Geodon® Capsules. Annual product sales in the U.S. of the capsules were approximately $760 million for the twelve months ended Dec 2006, based on IMS data.

"The approval of our Ziprasidone ANDA is our second approval in the CNS segment after our Sertraline ANDA. In particular, this approval reinforces Lupin's ability on submitting high quality dossiers at the right time and gaining approval well in time," said Dr. Kamal Sharma, Managing Director, Lupin.

With this approval, Lupin now has 22 ANDAs approved by the US FDA.

About Lupin
Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the financial year ended March 2007, Lupin's Revenues and Profit after Tax were Rs.20,289 million (US$ 475 million) and Rs. 3,021 million (US$ 70 million) respectively.

For further information contact:
Raju Kane
The Source
Tel. +91 22 24901327/28
Telefax: +91 22 24901325
Mobile: +91 98200 45656
E-mail: rajukane@sourcepr.com